<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CD6AF5C3-2280-4421-911E-1D68A6DFFE7C"><gtr:id>CD6AF5C3-2280-4421-911E-1D68A6DFFE7C</gtr:id><gtr:name>University of Wuerzburg</gtr:name><gtr:address><gtr:line1>Sanderring 2</gtr:line1><gtr:postCode>D-97070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/88077807-2572-4B6D-8467-0822C6A212BD"><gtr:id>88077807-2572-4B6D-8467-0822C6A212BD</gtr:id><gtr:name>NHS Blood and Transplant (NHSBT)</gtr:name><gtr:address><gtr:line1>Oak House
Reeds Crescent</gtr:line1><gtr:city>Watford</gtr:city><gtr:postCode>WD24 4QN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8F2AA65-FB13-45D8-96BA-E478CE387554"><gtr:id>A8F2AA65-FB13-45D8-96BA-E478CE387554</gtr:id><gtr:name>Karolinska University Hospital</gtr:name><gtr:address><gtr:line1>Karolinska University Hospital</gtr:line1><gtr:line2>Huddinge</gtr:line2><gtr:postCode>SE 141 86</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6F5F667B-3844-49DF-948F-FCA983560AF9"><gtr:id>6F5F667B-3844-49DF-948F-FCA983560AF9</gtr:id><gtr:name>Hannover Medical School</gtr:name><gtr:address><gtr:line1>Carl-Neuberg-Str. 1</gtr:line1><gtr:postCode>D-30625</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/61D20CC7-787C-455B-936A-3E16D0122205"><gtr:id>61D20CC7-787C-455B-936A-3E16D0122205</gtr:id><gtr:name>Semmelweis University</gtr:name><gtr:address><gtr:line1>Semmelweis University</gtr:line1><gtr:line2>Alkotas u. 44</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2F6044B9-9BC3-4ABA-9115-6AA15854A44A"><gtr:id>2F6044B9-9BC3-4ABA-9115-6AA15854A44A</gtr:id><gtr:name>University of Basel</gtr:name><gtr:address><gtr:line1>Petersplatz 1</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CD6AF5C3-2280-4421-911E-1D68A6DFFE7C"><gtr:id>CD6AF5C3-2280-4421-911E-1D68A6DFFE7C</gtr:id><gtr:name>University of Wuerzburg</gtr:name><gtr:address><gtr:line1>Sanderring 2</gtr:line1><gtr:postCode>D-97070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/88077807-2572-4B6D-8467-0822C6A212BD"><gtr:id>88077807-2572-4B6D-8467-0822C6A212BD</gtr:id><gtr:name>NHS Blood and Transplant (NHSBT)</gtr:name><gtr:address><gtr:line1>Oak House
Reeds Crescent</gtr:line1><gtr:city>Watford</gtr:city><gtr:postCode>WD24 4QN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8F2AA65-FB13-45D8-96BA-E478CE387554"><gtr:id>A8F2AA65-FB13-45D8-96BA-E478CE387554</gtr:id><gtr:name>Karolinska University Hospital</gtr:name><gtr:address><gtr:line1>Karolinska University Hospital</gtr:line1><gtr:line2>Huddinge</gtr:line2><gtr:postCode>SE 141 86</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6F5F667B-3844-49DF-948F-FCA983560AF9"><gtr:id>6F5F667B-3844-49DF-948F-FCA983560AF9</gtr:id><gtr:name>Hannover Medical School</gtr:name><gtr:address><gtr:line1>Carl-Neuberg-Str. 1</gtr:line1><gtr:postCode>D-30625</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/61D20CC7-787C-455B-936A-3E16D0122205"><gtr:id>61D20CC7-787C-455B-936A-3E16D0122205</gtr:id><gtr:name>Semmelweis University</gtr:name><gtr:address><gtr:line1>Semmelweis University</gtr:line1><gtr:line2>Alkotas u. 44</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2F6044B9-9BC3-4ABA-9115-6AA15854A44A"><gtr:id>2F6044B9-9BC3-4ABA-9115-6AA15854A44A</gtr:id><gtr:name>University of Basel</gtr:name><gtr:address><gtr:line1>Petersplatz 1</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DAECA10D-0993-488B-A15B-F062464CA324"><gtr:id>DAECA10D-0993-488B-A15B-F062464CA324</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>R</gtr:otherNames><gtr:surname>Wilkins</gtr:surname><gtr:orcidId>0000-0003-3926-1171</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_G0802523"><gtr:id>F189E7F7-FD95-4EB8-943D-2FD6A537BBC7</gtr:id><gtr:title>Expansion of the GMP facility for Stem Cell Therapy at Imperial College</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_G0802523</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Imperial College was awarded &amp;pound;1077K towards expansion of the GMP facility for stem cell therapy at the Hammersmith Campus. This will help to alleviate the current crisis in capacity, and the proposed investment would bring substantial added value.|Stem cell research and its translational embodiment (regenerative medicine) are presently among the most auspicious aspects of discovery biology and its application to the bedside.|Cell-based therapies have long-standing and venerable importance in the treatment of hematological disorders, including the restitution of bone marrow after cancer chemotherapy. Bone marrow-derived stem cells include not only hematopoietic stem cells (HSCs) that reconstitute the blood-forming lineages but also bone marrow stromal cells (mesenchymal stem cells; MSCs). Both have been deployed as potential therapies across a wide spectrum of human disorders, in successful Phase I and Phase II clinical trials.|The scientific principles underpinning these cells beneficial effects are a matter of intensive study, but include the secretion of angiogenic, cytoprotective, immunosuppressive, and|wound-healing factors, beyond merely the suggested possibility, in some cases, of bona fide regeneration. By contrast, the ability to create new heart muscle or neurons, for example, is unquestioned in the case of embryonic stem (ES) cells derived from the|blastocyst or in the case of novel progenitor and stem cells that have been newly defined in the heart, brain, and other organs. Furthermore, the forced expression of stemness |transcription factors in adult fibroblasts or other adult somatic cells and the resulting creation of induced pluripotent stem cells provides uncanny opportunities to investigate patient-specific ES cell-like cells, as new models of human disorders or as new avenues of|therapy.|In short, the inherent attractiveness, logic, allure and scientific timeliness of cell-based approaches offers the promise of revolutionary advances in regenerative medicine, for|many of the most complex, prevalent, and challenging diseases.</gtr:technicalSummary><gtr:fund><gtr:end>2011-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1076974</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Basel</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Department of Biomedicine</gtr:department><gtr:description>Production of GMP-grade mesenchymal stem cells using 3-D scaffolds in bioreactors: clinical safety and efficacy</gtr:description><gtr:id>2C759A29-3A72-4F8B-836C-A5F934C8F33F</gtr:id><gtr:impact>The collaboration has started very recently but we have submitted a large European grant (? 5,000,000) to fund the initiative. If successful, this project will enable us to produce large numbers of MSC for clinical use and make them available to several Clinical Centres. The collaborations involves different disciplines: Haematology, Immunology, Tissue engineering</gtr:impact><gtr:outcomeId>YGvjkEAXujh-1</gtr:outcomeId><gtr:partnerContribution>They provide bioreactors for growing mesenchymal stem cellsThey will contribute to test safety and efficacy of mesenchymal stem cells grown in bioreactors for the treatment of patients with severe graft-versus-host diseaseThey will contribute to test safety and efficacy of mesenchymal stem cells grown in bioreactors for the treatment of patients with severe graft-versus-host disease</gtr:partnerContribution><gtr:piContribution>We have initiated this collaboration with a view of bringing bioreactors into the clinical preparation of cell therapies. We will test their use and feasibility in GMP conditions and eventually prepare the cells to be delivered at the participating clinical Centres (Hammersmith, Stockholm, Budapest). We will also assess the therapeutic potency of the MSC thus generated using a number of assays developed at our Centre</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska University Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Department of Hematology</gtr:department><gtr:description>Production of GMP-grade mesenchymal stem cells using 3-D scaffolds in bioreactors: clinical safety and efficacy</gtr:description><gtr:id>FF3E270E-6BCB-4BFE-9C5D-74CC6FE6E1C1</gtr:id><gtr:impact>The collaboration has started very recently but we have submitted a large European grant (? 5,000,000) to fund the initiative. If successful, this project will enable us to produce large numbers of MSC for clinical use and make them available to several Clinical Centres. The collaborations involves different disciplines: Haematology, Immunology, Tissue engineering</gtr:impact><gtr:outcomeId>YGvjkEAXujh-2</gtr:outcomeId><gtr:partnerContribution>They provide bioreactors for growing mesenchymal stem cellsThey will contribute to test safety and efficacy of mesenchymal stem cells grown in bioreactors for the treatment of patients with severe graft-versus-host diseaseThey will contribute to test safety and efficacy of mesenchymal stem cells grown in bioreactors for the treatment of patients with severe graft-versus-host disease</gtr:partnerContribution><gtr:piContribution>We have initiated this collaboration with a view of bringing bioreactors into the clinical preparation of cell therapies. We will test their use and feasibility in GMP conditions and eventually prepare the cells to be delivered at the participating clinical Centres (Hammersmith, Stockholm, Budapest). We will also assess the therapeutic potency of the MSC thus generated using a number of assays developed at our Centre</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Plastic and Reconstructive Surgery</gtr:department><gtr:description>Mesenchymal stem cells and allogeneic keratinocytes for the treatment of skin wounds</gtr:description><gtr:id>B95A29FD-1ADE-4C98-8FBD-4203A23187F1</gtr:id><gtr:impact>The collaboration is at its early stage but we have already treated one compassionate case with some success. This will put us in the position to apply for a translational grant in the next three months. The collaboration includes different disciplines: Haematology, Immunology, Plastic Surgery</gtr:impact><gtr:outcomeId>Meb8tyNFbDY-1</gtr:outcomeId><gtr:partnerContribution>They test the safety and efficacy of combining MSC and allogeneic keratinocyte preparations on patients affected by slow healing skin wounds.</gtr:partnerContribution><gtr:piContribution>We are responsible for the cell preparations and provide them to test in the patients</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Wurzburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Department of Hematology and Transplantation</gtr:department><gtr:description>Efficacy and Safety of Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR?) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor</gtr:description><gtr:id>7E27B254-BF96-4FE1-9C00-08311D4B4356</gtr:id><gtr:impact>The clinical trial is registered on the clinicaltrials.gov website NCT00967343. The trial opened for recruitment in September 2009 and 26 patients across Europe an north America have been recruited. A preliminary report of the data so far will be presented at the European Blood and Marrow Transplantation Meeting in Paris in April 2011.</gtr:impact><gtr:outcomeId>P83YZAAo26L-1</gtr:outcomeId><gtr:partnerContribution>this collaboration has resulted in a multi-centre clinical trial of a novel haploidentical transplantation approach. We will study the effects of the administration of donor lymphocytes, selectively depleted of host alloreactive T-cells (through the ex-vivo use of TH9402 dye and light) to restore immunity more rapidly, with the aim of limiting the number of infections and infection-related deaths.</gtr:partnerContribution><gtr:piContribution>we have been directly involved in the development of the clinical trial, including the laboratory aspects of the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Semmelweiss University</gtr:collaboratingOrganisation><gtr:country>Hungary, Republic of</gtr:country><gtr:department>Haematology</gtr:department><gtr:description>Production of GMP-grade mesenchymal stem cells using 3-D scaffolds in bioreactors: clinical safety and efficacy</gtr:description><gtr:id>B4CA8C17-7791-475C-88DD-B832DC52A24E</gtr:id><gtr:impact>The collaboration has started very recently but we have submitted a large European grant (? 5,000,000) to fund the initiative. If successful, this project will enable us to produce large numbers of MSC for clinical use and make them available to several Clinical Centres. The collaborations involves different disciplines: Haematology, Immunology, Tissue engineering</gtr:impact><gtr:outcomeId>YGvjkEAXujh-3</gtr:outcomeId><gtr:partnerContribution>They provide bioreactors for growing mesenchymal stem cellsThey will contribute to test safety and efficacy of mesenchymal stem cells grown in bioreactors for the treatment of patients with severe graft-versus-host diseaseThey will contribute to test safety and efficacy of mesenchymal stem cells grown in bioreactors for the treatment of patients with severe graft-versus-host disease</gtr:partnerContribution><gtr:piContribution>We have initiated this collaboration with a view of bringing bioreactors into the clinical preparation of cell therapies. We will test their use and feasibility in GMP conditions and eventually prepare the cells to be delivered at the participating clinical Centres (Hammersmith, Stockholm, Budapest). We will also assess the therapeutic potency of the MSC thus generated using a number of assays developed at our Centre</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hannover Medical School</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>Academic GMP</gtr:description><gtr:id>2316F03B-E741-40EC-9581-820B65363479</gtr:id><gtr:impact>Kickoff meeting in Septenber 2010. First milestones have not yet been reached</gtr:impact><gtr:outcomeId>bxDvwy9yK12-1</gtr:outcomeId><gtr:partnerContribution>We were invited to participate in an EU Framework 7 project entitled &amp;quot;The impact of regulation (EC) No 1394/2007 on the development of Advanced Therapy Medicinal Products (ATMPs): an academic perspective&amp;quot;. The project brings together eight European groups considered to be expert in the academic production of cells for human use.</gtr:partnerContribution><gtr:piContribution>The main objective of the research consortium is to generate new knowledge on the impact of advanced therapies regulations in the field of both academic sectors as well as on regulatory authorities and various stakeholders. Our role is in an advisory capacity, hence the limited funding, but we occupy an influential role in the project. In part because of the adverse impact of the U Clinical Trials Directive on academic led investogator trials we were anxious that the same did not occur in the provision of cellular therapy by academic institutions. We hope to present concrete and important suggestions to policy makers as to how the ATMP regulations are impacting on the academic sector</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Blood and Transplant (NHSBT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Banking of mesenchymal stem cells for the treatment of graft-versus-host disease</gtr:description><gtr:id>6231734A-6EFC-4297-BE2D-CFD4B184D9D9</gtr:id><gtr:impact>We have only recently established the collaboration and we are now in the position to apply for a large NIHR grant to test the feasibility of establishing a central collection of MSC batches and distribute them to the Clinical Centres for the treatment of patients with graft-versus-host disease. The collaboration involves different disciplines: Haematology, Immunology, Pediatrics.</gtr:impact><gtr:outcomeId>pqEcTCnGbHD-1</gtr:outcomeId><gtr:partnerContribution>NBS provides facilities to grow mesenchymal stem cells and the storage for banking frozen batches</gtr:partnerContribution><gtr:piContribution>We have initiated mesenchymal stem cell (MSC) expansions for clinical use in the country and treated a number of patients. Therefore, we will provide the guidelines and the expertise to enable the other NBS facilities to start MSC production. We have also developed the screenings to assess MSC potency</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Brain Sciences</gtr:department><gtr:description>Mesenchymal stem cells for the treatment of multiple sclerosis: a phase II clinical trial</gtr:description><gtr:id>7F48D44E-2C12-4EDE-A330-64B983C34207</gtr:id><gtr:impact>We have submitted a grant (&amp;pound;500,000) to fund the costs of the trial including cell preparation and the assessment procedures. It has been shortlisted and is currently being considered in the final stage of the competition. The collaboration involves different disciplines: Haematology, Immunology, Neurology.</gtr:impact><gtr:outcomeId>ozjbQsTyYmh-1</gtr:outcomeId><gtr:partnerContribution>They will test mesenchymal stem cells to improve patients with aggressive forms of multiple sclerosis by cinducting a phase II clinical trial</gtr:partnerContribution><gtr:piContribution>We will prepare the mesenchymal stem cells in our facility and assess some of the immunological parameters following the cell infusion</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>Exploitation of the innate immune response in cancer and development of GMP grade Natural Killer cells for adoptive transfer in the treatment of hematological malignancies</gtr:description><gtr:id>30587DE1-2D64-4008-9EAB-988D4CC316BC</gtr:id><gtr:impact>PMID: 20562327</gtr:impact><gtr:outcomeId>nNmcMBYBSBv-1</gtr:outcomeId><gtr:piContribution>We have successfully scaled up the production of GMP grade NK cells that can be generated from healthy donors and infused into patients following allogeneic stem cell transplantation to prevent or treat relapse. A phase 1 dose escalation study to assess the safety of this approach will open for recruitment soon.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient and Family Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>145C08B5-63A8-46E1-BD20-25608DEC3A94</gtr:id><gtr:impact>In April 2013 we wil host a patient and family day for 400 patiets and their carers who have been affected by transplant

We predict this will be much appreacited by patients but we will formally evaluate the day</gtr:impact><gtr:outcomeId>PN4HPHzQKPY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to fund raisers</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9DC190CC-5CDF-4AE4-B074-BB01BC23285B</gtr:id><gtr:impact>Potential donors have been invited to visit the unit and discuss our owrk

Increased funding to our local charity</gtr:impact><gtr:outcomeId>cyGavY4xeBT</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Local fund-raisers</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EE48B3A2-C0D7-4CBF-A374-F00EE41FA93A</gtr:id><gtr:impact>We have a local fund-raising activity in the form of our own charity. Funds raised by these individuals actually built the building in which the GMP lab is housed and they also helped to fund the construction of the lab and its equipment. We regularly host established and new fund-raisers, (probably now more than 200), explaining the nature of stem cell transplantation, its potential in regenerative medicine and showing then around the laboratory

Continued highly successful local fund-raising for equipment, bridging money for staff etc</gtr:impact><gtr:outcomeId>MYmf6hMzo4m</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>school visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>89A33572-B204-4BA6-B734-C73ECD279367</gtr:id><gtr:impact>Twice a year we host a visit by 12 6th formers from local school (so total now about 70) who plan to read medicine or science at university, explaining to them the nature of stem cell transplant, its potential wider applications, its current use and its current limitations

Schools always express deep appreciation, 6th formers write up visits in school magazines recommending participation to other students. One school has sent us 12 students over the three years and all 12 have subsequently applied for medicine</gtr:impact><gtr:outcomeId>EruMFyN6wEg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to fund raisers</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D8CCE4B4-D43B-47EE-9B1B-53736A334C3E</gtr:id><gtr:impact>Presentation to 300 fund-raisers for Leukaemia and Lymphoma Society, explaining future and wider applications of stem cell transplant

Appreciation voiced by LLR staff and by fund-raisers themselves</gtr:impact><gtr:outcomeId>HUY737j9ixj</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme grant</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>EDA1357A-D96E-4913-BCAA-65E8522C13D9</gtr:id><gtr:outcomeId>JYm5KFLBEVA0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>460000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical trial of DNA vaccine for WT1 in haematological malignancies</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>C3AE8D17-85A7-4B6A-8916-F41AECC76E77</gtr:id><gtr:outcomeId>KPKnZbZFhzi</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>The Kay Kendall Leukaemia Fund (KKLF)</gtr:fundingOrg><gtr:id>9F3FC80D-2CDC-407E-8544-E2805665DDD4</gtr:id><gtr:outcomeId>A3dS7VrnCnp0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European committe for the release criteria of mesenchymal stem cells for clinical use</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>1339C2F1-9247-48C6-89D6-6F65F38951F7</gtr:id><gtr:outcomeId>MCWgp8gsofH</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European consensus group on optimal mobilisation schedules</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>3256AB54-F3D6-462C-A3CF-A43D92734390</gtr:id><gtr:outcomeId>jAsTmqx1Gve</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>NK cells are a subset of T-lymphocytes with potential anti-tumour effects. This activity is fully funded from this grant. Associated laboratory studies funded through Biomedical Research Centre grant</gtr:description><gtr:id>EEF7FBA8-B4F8-4AD4-A765-0354418310AE</gtr:id><gtr:impact>Too early to assess impact</gtr:impact><gtr:outcomeId>jLXUVc3UVks</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>NK cells</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Large scale prduction of autologous anti-CMV lymphocytes now achieved. Phase I/II trial protocol completed, ethics applications currently submitted. Fully funded through this grant</gtr:description><gtr:id>C4F5C729-1B33-4CEF-AB87-1A2ECB68D8B2</gtr:id><gtr:impact>No impact as yet</gtr:impact><gtr:outcomeId>bseWrrqhmV7</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Autologous anti-CMV specific T-cells</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We are now growing MSC from most of stem cell transplant donors for use as third party donations for patients with life-threatening GvHD in a phase II clinical study. Fully funded throughthis grant</gtr:description><gtr:id>1F3D432E-E77B-4F0E-9991-89067E07E91D</gtr:id><gtr:impact>Control of steroid refractory life threatening GvHD in 40% of sufferers</gtr:impact><gtr:outcomeId>Hjz11Z1Aw4k</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Mesenchymal stem cells for treatment of GvHD</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>This establishes a clinical-scale process capable of highly efficient, reproducible, selective removal of alloreactive lymphocytes from lymphocyte transplant products performed under current Good Manufacturing Practice</gtr:description><gtr:id>70C8060D-1B31-431F-808E-12F9EF7B9A9D</gtr:id><gtr:impact>We are participating in a multi-centre study of the use of these cells in clinical transplant. At present we are nnot producing these cells locally but because of our expertise, excellent lab facilities and increased infra-structure consequent on this grant, we are being considered as potential producers if the initial results are promising</gtr:impact><gtr:outcomeId>jdSMefv3uy9</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Selective allo-depleted stem cell product for stem cell transplant</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>NK cells are a sub-population of lymphocytes thought to have anti-tumour activity</gtr:description><gtr:id>F0474F63-2DAB-4666-9993-80C592880452</gtr:id><gtr:impact>Scale-up of NK cell production has now completed enabling the development of a phase I/II clinical study.</gtr:impact><gtr:outcomeId>ih5TGovehZ9</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>NK cells</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>MSC developed from adherent cells grown from human bone marrow and used for the treatment of GvHD and graft failure in the context of stem cell transplantation</gtr:description><gtr:id>C4BF3392-BA5B-4D4D-912B-1F762C358D04</gtr:id><gtr:impact>Offers an alternative therapy for treatment of complications of stem cell transplant</gtr:impact><gtr:outcomeId>ePhRJTWaWb3</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>mesenchymal stem cells (MSC)</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>T-lymphocytes directed against antigens presented by CMV infected cells</gtr:description><gtr:id>4634C938-9852-4372-BB57-DF82EE843FF4</gtr:id><gtr:impact>Optimistion of cell selection and explansion has facilitated development of a novel phase I/II clinical trial to investigate the use of autologous anti-CMV specific T-cells for CMV disease after allogeneic stem cell transplant</gtr:impact><gtr:outcomeId>cdubTxQfPE8</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CMV specific T-cells</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B5558B09-F21F-43D0-8388-61D24C4C0024</gtr:id><gtr:title>Regulation of donor participation in research studies: is there another way?</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80279c728ad78bb0755364ab9c514a47"><gtr:id>80279c728ad78bb0755364ab9c514a47</gtr:id><gtr:otherNames>Apperley JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>pm_16224_24_21076474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33106ED1-127C-428B-A3A1-C550B0D8F810</gtr:id><gtr:title>Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a94c2200c26d54b2ee7677ec9693020f"><gtr:id>a94c2200c26d54b2ee7677ec9693020f</gtr:id><gtr:otherNames>Gratwohl A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>pm_16224_24_20378578</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6590798-4653-4DAE-9098-E235E988F1FB</gtr:id><gtr:title>The immunosuppressive properties of mesenchymal stem cells.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0602dbc147feb797fdde1e9472dab97"><gtr:id>a0602dbc147feb797fdde1e9472dab97</gtr:id><gtr:otherNames>Siegel G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>pm_16224_14_19424005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C7068DF-B03F-44B3-80FA-C219C9D7A64E</gtr:id><gtr:title>Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97cdb892bd28119895c5dee797659702"><gtr:id>97cdb892bd28119895c5dee797659702</gtr:id><gtr:otherNames>Galleu A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>5aa7793f367b39.14882438</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86D38491-0C2D-43AB-B650-EFAC20600A92</gtr:id><gtr:title>High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma.</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7b66591a70722ef84d0d2def98a8fa4"><gtr:id>b7b66591a70722ef84d0d2def98a8fa4</gtr:id><gtr:otherNames>Auner HW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>rakCx5N5hwJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA96DE0E-0C33-4BB4-9A88-315AD6B48CD6</gtr:id><gtr:title>Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/628a5e138ebeff715deac5530c001b06"><gtr:id>628a5e138ebeff715deac5530c001b06</gtr:id><gtr:otherNames>Lymperi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_16224_24_21131587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>963B5F3A-2E56-4F6D-B9C1-BC40DD8B6A9D</gtr:id><gtr:title>Impact of the European clinical trials directive on prospective academic clinical trials associated with BMT.</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/892a5a8b78aa4fce54fae57b0d11dfec"><gtr:id>892a5a8b78aa4fce54fae57b0d11dfec</gtr:id><gtr:otherNames>Frewer LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>pm_16224_24_20531283</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1D08E17-B2C7-4616-82AF-00EB7AA1CCA4</gtr:id><gtr:title>Mesenchymal stem cells: the fibroblasts' new clothes?</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75514f8f493721a6cccc79f8b42738d1"><gtr:id>75514f8f493721a6cccc79f8b42738d1</gtr:id><gtr:otherNames>Haniffa MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>pm_16224_14_19109217</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58EB9D7D-B415-4B6B-AF1B-EDDC6F366E10</gtr:id><gtr:title>Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation.</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbf2aa1f06a7ff31b3c5a15f315f15b7"><gtr:id>bbf2aa1f06a7ff31b3c5a15f315f15b7</gtr:id><gtr:otherNames>Pavlu J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>5aa7793f03c6a9.69069546</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAB27D53-ECEB-43C3-A789-4359EEA4890E</gtr:id><gtr:title>Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT.</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a282197b319c387db8035e55fdf293c"><gtr:id>6a282197b319c387db8035e55fdf293c</gtr:id><gtr:otherNames>Chalandon Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>UCyizFAcpQw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F13D4AAA-2954-4403-81B3-5F5C33D66DB1</gtr:id><gtr:title>Has the European Clinical Trials Directive been a success?</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/892a5a8b78aa4fce54fae57b0d11dfec"><gtr:id>892a5a8b78aa4fce54fae57b0d11dfec</gtr:id><gtr:otherNames>Frewer LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>5a6f530535ab23.34044167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6243998E-647E-481A-B1B3-3C8CF7661107</gtr:id><gtr:title>JACIE accreditation in 2008: demonstrating excellence in stem cell transplantation.</gtr:title><gtr:parentPublicationTitle>Hematology/oncology and stem cell therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15ca2e6284caaba2389a232e728f843a"><gtr:id>15ca2e6284caaba2389a232e728f843a</gtr:id><gtr:otherNames>Pamphilon D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>pm_16224_24_20118054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A16218F-3F84-4C49-BA5D-7707B614D5FC</gtr:id><gtr:title>Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9a1b3d0bc55e06ade5b2c73544881a6"><gtr:id>c9a1b3d0bc55e06ade5b2c73544881a6</gtr:id><gtr:otherNames>Vianello F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>PRcKCnkzQ2J</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>370D4F13-887C-4BC2-94B8-E33E410A8ACB</gtr:id><gtr:title>Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6ee3b0ca2eed1cf3a54c224c94230e5"><gtr:id>c6ee3b0ca2eed1cf3a54c224c94230e5</gtr:id><gtr:otherNames>Shaw BE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>EbAamjErxPt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84B39271-1C3E-4CE1-9ED1-4DE7E79B5A27</gtr:id><gtr:title>The therapeutic activity of low-dose irradiation on experimental arthritis depends on the induction of endogenous regulatory T cell activity.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e8904039c8c9bcce2c9bcc04f7411a9"><gtr:id>7e8904039c8c9bcce2c9bcc04f7411a9</gtr:id><gtr:otherNames>Weng L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>cexvvgTGEh8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45C1018D-9791-4578-9706-5648ABB989AB</gtr:id><gtr:title>Regulatory T cells in stem cell transplantation: main characters or walk-on actors?</gtr:title><gtr:parentPublicationTitle>Critical reviews in oncology/hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e05172b154e07ee7af8d05d6ef9c5f5d"><gtr:id>e05172b154e07ee7af8d05d6ef9c5f5d</gtr:id><gtr:otherNames>Fozza C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1040-8428</gtr:issn><gtr:outcomeId>pm_16224_24_22386896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>498CB988-84D5-4EA6-BF83-74C512C81A66</gtr:id><gtr:title>Haemopoietic stem cell transplantation induces tolerance to donor antigens but not to foreign FVIII peptides.</gtr:title><gtr:parentPublicationTitle>Haemophilia : the official journal of the World Federation of Hemophilia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83901a82ef8f48d5923c0cb0cd05dd98"><gtr:id>83901a82ef8f48d5923c0cb0cd05dd98</gtr:id><gtr:otherNames>Uprichard J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1351-8216</gtr:issn><gtr:outcomeId>EnM3HqKv9QQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51A365B4-D657-486A-BE78-9B813FB6230F</gtr:id><gtr:title>European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f76b6799b1c5c9dd0e8ff824ddccd80"><gtr:id>3f76b6799b1c5c9dd0e8ff824ddccd80</gtr:id><gtr:otherNames>Worel N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>pm_16224_24_22414093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72D1F5E9-DB87-4059-A8C6-0272885AFAE8</gtr:id><gtr:title>Lymphodepletion chemotherapy followed by donor leukocytes for post-transplantation relapse of myelofibrosis after previous donor leukocyte infusion failure.</gtr:title><gtr:parentPublicationTitle>European journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84b697c98764230f6c13efd63c5422e2"><gtr:id>84b697c98764230f6c13efd63c5422e2</gtr:id><gtr:otherNames>Neave EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0902-4441</gtr:issn><gtr:outcomeId>pm_16224_24_23110685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0F88A53-08A5-46F9-AF4B-9410CDED3C68</gtr:id><gtr:title>Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e02572b58051028a9bfbf20532fd6176"><gtr:id>e02572b58051028a9bfbf20532fd6176</gtr:id><gtr:otherNames>Chaidos A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_16224_24_22371885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3355B771-24C0-4C22-87D2-2866BD3B18F2</gtr:id><gtr:title>Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation.</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ccbb3492d111dbadd943b7907ff9931"><gtr:id>2ccbb3492d111dbadd943b7907ff9931</gtr:id><gtr:otherNames>Basak GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>pm_16224_24_23178548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44697860-A119-40C9-A8A3-E3E645E7100D</gtr:id><gtr:title>JACIE celebrates its 10-year anniversary with the demonstration of improved clinical outcome.</gtr:title><gtr:parentPublicationTitle>Cytotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/383c0f9f9c7091b5c98f919bda65d35a"><gtr:id>383c0f9f9c7091b5c98f919bda65d35a</gtr:id><gtr:otherNames>Chabannon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1465-3249</gtr:issn><gtr:outcomeId>pm_16224_24_21299363</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1658F784-50F7-441D-872A-E0F8579DE655</gtr:id><gtr:title>Mesenchymal stem cells and autoimmune diseases.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c7b6b82255d52e08066c26becfff006"><gtr:id>1c7b6b82255d52e08066c26becfff006</gtr:id><gtr:otherNames>Dazzi F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1521-6926</gtr:issn><gtr:outcomeId>pm_16224_24_21396592</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD8953A4-9960-4C72-BB86-C50D1DD22737</gtr:id><gtr:title>European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e500ed7324d8b4e866ff2622886ed121"><gtr:id>e500ed7324d8b4e866ff2622886ed121</gtr:id><gtr:otherNames>H?bel K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>pm_16224_24_22080971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE5D7045-10DD-4C27-914B-4E8AC2955E18</gtr:id><gtr:title>The immunomodulatory properties of mesenchymal stem cells.</gtr:title><gtr:parentPublicationTitle>Seminars in immunopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/703c9f664a9aa1f1ba85668d6c85fa18"><gtr:id>703c9f664a9aa1f1ba85668d6c85fa18</gtr:id><gtr:otherNames>Marigo I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1863-2297</gtr:issn><gtr:outcomeId>pm_16224_24_21499984</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E259B18C-C40B-4398-B44F-BC695CFD7767</gtr:id><gtr:title>Primary plasma cell leukemia and autologous stem cell transplantation.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c1d49e4e1519ca215904b58c2f761b0"><gtr:id>0c1d49e4e1519ca215904b58c2f761b0</gtr:id><gtr:otherNames>Drake MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>585d63bcc70998.10805429</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BFC44A6-1DB3-4A76-A773-5AEE6CBEC2AD</gtr:id><gtr:title>Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF.</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ccbb3492d111dbadd943b7907ff9931"><gtr:id>2ccbb3492d111dbadd943b7907ff9931</gtr:id><gtr:otherNames>Basak GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>pm_16224_24_21986638</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BD9D0B6-BB7D-4982-8944-2CCBAE8345F7</gtr:id><gtr:title>Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate.</gtr:title><gtr:parentPublicationTitle>Cytotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5acb7e53c0021e259e55481165df1571"><gtr:id>5acb7e53c0021e259e55481165df1571</gtr:id><gtr:otherNames>Capelli C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1465-3249</gtr:issn><gtr:outcomeId>pm_16224_24_21417678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9F04EE4-E186-477F-9E11-839E6F6574C0</gtr:id><gtr:title>Basic research and clinical applications of non-hematopoietic stem cells, 4-5 April 2008, Tubingen, Germany.</gtr:title><gtr:parentPublicationTitle>Cytotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4a0e069639e00b41ac8fcbb74d4c803"><gtr:id>b4a0e069639e00b41ac8fcbb74d4c803</gtr:id><gtr:otherNames>Sch?fer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1465-3249</gtr:issn><gtr:outcomeId>pm_16224_14_19152153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B9D974B-B180-4C13-82AB-A6C10C5F937D</gtr:id><gtr:title>Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c99120a434120c58fdf5a40607136dde"><gtr:id>c99120a434120c58fdf5a40607136dde</gtr:id><gtr:otherNames>Gabriel IH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>EU1ExrwNCH7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2C86F76-F754-4879-B9AC-8EBE9BD613CB</gtr:id><gtr:title>LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre.</gtr:title><gtr:parentPublicationTitle>Hematological oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbf2aa1f06a7ff31b3c5a15f315f15b7"><gtr:id>bbf2aa1f06a7ff31b3c5a15f315f15b7</gtr:id><gtr:otherNames>Pavlu J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0278-0232</gtr:issn><gtr:outcomeId>YwkXaiqDzjN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E81CBAE-DC47-401B-8B5E-435B97A7AA14</gtr:id><gtr:title>Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46a6e4f9cd3e432b811438d45728a3da"><gtr:id>46a6e4f9cd3e432b811438d45728a3da</gtr:id><gtr:otherNames>Dickinson AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>pm_16224_24_20305143</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B7DDC49-ADF7-4A5C-A138-4FB2EF2B0987</gtr:id><gtr:title>Efficacy and outcome of autologous transplantation in rare myelomas.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/879042325d3c977391eb4e1505b7fdd6"><gtr:id>879042325d3c977391eb4e1505b7fdd6</gtr:id><gtr:otherNames>Morris C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>KJ9Ycwi5QkD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DECD799-FCB1-4975-ACF5-FFEB00A4D154</gtr:id><gtr:title>BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation.</gtr:title><gtr:parentPublicationTitle>European journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/551f8de0f973ce92210711b187e34363"><gtr:id>551f8de0f973ce92210711b187e34363</gtr:id><gtr:otherNames>Pello OM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0902-4441</gtr:issn><gtr:outcomeId>5a578c0fefa9b4.81455884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D781628D-55A6-4277-A178-C54395771FA7</gtr:id><gtr:title>Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program.</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/383c0f9f9c7091b5c98f919bda65d35a"><gtr:id>383c0f9f9c7091b5c98f919bda65d35a</gtr:id><gtr:otherNames>Chabannon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>pm_16224_24_21383685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4E0BB6D-FA7C-41E7-8E00-9949F6409B73</gtr:id><gtr:title>Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance?</gtr:title><gtr:parentPublicationTitle>Immunology and cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fbc4ca8ba5003117f7675215adb2c25"><gtr:id>7fbc4ca8ba5003117f7675215adb2c25</gtr:id><gtr:otherNames>Burr SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0818-9641</gtr:issn><gtr:outcomeId>pm_16224_24_23146942</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1390A03B-A7E4-429B-92C9-2E72E682DD58</gtr:id><gtr:title>Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7b66591a70722ef84d0d2def98a8fa4"><gtr:id>b7b66591a70722ef84d0d2def98a8fa4</gtr:id><gtr:otherNames>Auner HW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_16224_24_22050411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0205ED4B-2D93-486D-B56E-792DA9B7864E</gtr:id><gtr:title>Mesenchymal stromal cells: a key player in 'innate tolerance'?</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c7b6b82255d52e08066c26becfff006"><gtr:id>1c7b6b82255d52e08066c26becfff006</gtr:id><gtr:otherNames>Dazzi F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>pm_16224_24_22804624</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0C61D32-62C3-4315-A690-3400CA1DC441</gtr:id><gtr:title>Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.</gtr:title><gtr:parentPublicationTitle>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/004d86d3b6a7a5803c1d6d71ee2350ca"><gtr:id>004d86d3b6a7a5803c1d6d71ee2350ca</gtr:id><gtr:otherNames>Malard F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1083-8791</gtr:issn><gtr:outcomeId>pm_16224_24_22001752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D01D5B9E-3A5D-4E35-8908-115E6DFC100C</gtr:id><gtr:title>Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc93b4050b127ad6218c02f76d6af1bf"><gtr:id>dc93b4050b127ad6218c02f76d6af1bf</gtr:id><gtr:otherNames>Gorin NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_16224_24_20479285</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4160E71C-C969-49B8-A723-AE7EE476A1CC</gtr:id><gtr:title>Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7184aab4ae0609de1adae2cbdb444c6"><gtr:id>d7184aab4ae0609de1adae2cbdb444c6</gtr:id><gtr:otherNames>Ciceri F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>WSYLMKdgLVu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC014100-18F0-46D8-AC4E-217A20716019</gtr:id><gtr:title>Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c739f6d7ee6a3638cb6f06ad7c01d570"><gtr:id>c739f6d7ee6a3638cb6f06ad7c01d570</gtr:id><gtr:otherNames>Wahl S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>5a578bd1980f17.06467020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C2DB122-6C3D-4BC3-9C2C-BDB9CA3D81CE</gtr:id><gtr:title>Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbf2aa1f06a7ff31b3c5a15f315f15b7"><gtr:id>bbf2aa1f06a7ff31b3c5a15f315f15b7</gtr:id><gtr:otherNames>Pavlu J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>cEmcdNN7UTs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99043E3C-707E-4F4C-83DC-A09798FE0AE5</gtr:id><gtr:title>The EBMT activity survey 2008: impact of team size, team density and new trends.</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a94c2200c26d54b2ee7677ec9693020f"><gtr:id>a94c2200c26d54b2ee7677ec9693020f</gtr:id><gtr:otherNames>Gratwohl A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>pm_16224_24_20348970</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59A13A8C-F245-4FE4-B634-572E1C0B6708</gtr:id><gtr:title>A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bca9710e3dc0a25e25fb349bdbc954e"><gtr:id>2bca9710e3dc0a25e25fb349bdbc954e</gtr:id><gtr:otherNames>Mielke S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>SGPqahbMLsa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70A6C51B-225E-4AB9-98FC-70FCA508489D</gtr:id><gtr:title>Monomeric, porous type II collagen scaffolds promote chondrogenic differentiation of human bone marrow mesenchymal stem cells in vitro.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1565c32c2d0e731233aa7f28ac58c79f"><gtr:id>1565c32c2d0e731233aa7f28ac58c79f</gtr:id><gtr:otherNames>Tamaddon M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a578be1baa421.66981554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A48ABB4B-46DD-467A-B8B9-28BB0E0FE982</gtr:id><gtr:title>Effects of MSC co-injection on the reconstitution of aplastic anemia patient following hematopoietic stem cell transplantation.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2479f244939321160b1822521727728c"><gtr:id>2479f244939321160b1822521727728c</gtr:id><gtr:otherNames>Jaganathan BG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>TYWm3AaHsCR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>502EA0CF-845D-4A0F-99C4-2D35B5E51378</gtr:id><gtr:title>Regulatory T cell therapy for the induction of clinical organ transplantation tolerance.</gtr:title><gtr:parentPublicationTitle>Seminars in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50e14e343cce5857955cfbb8534aeca3"><gtr:id>50e14e343cce5857955cfbb8534aeca3</gtr:id><gtr:otherNames>Fan H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1044-5323</gtr:issn><gtr:outcomeId>pm_16224_24_21920772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8C1CEC4-B993-426D-97E6-32B99854511A</gtr:id><gtr:title>Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a94c2200c26d54b2ee7677ec9693020f"><gtr:id>a94c2200c26d54b2ee7677ec9693020f</gtr:id><gtr:otherNames>Gratwohl A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>pm_16224_24_21483006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E00965D-7550-4745-AFFB-EAB2D384EAC7</gtr:id><gtr:title>The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/327c123dac19d2528c3cec880ed91b4d"><gtr:id>327c123dac19d2528c3cec880ed91b4d</gtr:id><gtr:otherNames>Stewart WA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>Ff25CHVSGUe</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_G0802523</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>986F1CAE-CC43-4D59-8F85-A91971E4C4BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Other</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1A41A859-2076-46E6-B80F-CE4E1E8EDC1D</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.5  Resources and infrastructure (underpinning)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>